For research use only. Not for therapeutic Use.
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D)[1][2][3].
Cotadutide acetate stimulates a concentration-dependent increase in cAMP accumulation in rat (INS-1 832/3) and human (EndoC-βH1) β-cell lines (EC50: 226 pM and 1051 pM, respectively ), as well as rat, mouse and human hepatocytes (EC50: 462 pM, 840 pM, 1447 pM, respectively)[1].
Cotadutide (100 pM-1 μM) acetate potentiates glucose-stimulated insulin secretion in the rat (INS-1 832/3) pancreatic β‐cell line and increases glucose output in rat hepatocytes[1].
Cotadutide (100 nM, 2 h) acetate induces mitochondrial turnover and enhances mitochondrial function in mouse primary hepatocytes[2].
Cotadutide (10 nmol/kg, s.c., once) acetate suppresses food intake in DIO mice relative to vehicle‐treated controls[1].
Cotadutide (10 or 30 nmol/kg, s.c., once daily for 14-16 weeks) acetate reduces body weight in DIO mice[1].
Cotadutide (30 nmol/kg, s.c., once a day for 6 weeks) acetate reduces hepatic fibrosis and inflammation in in ob/ob AMLN NASH mice[2].
| Catalog Number | I045973 |
| Molecular Formula | C169H256N42O57 |
| Purity | ≥95% |
| Reference | [1]. Henderson SJ,et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.Diabetes Obes Metab. 2016 Dec;18(12):1176-1190. [2]. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020 May;2(5):413-431. |
